Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy

References

• Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N;Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94
   PubMed Web of Science ®Google Scholar
• Utian WH, Archer DF, Bachmann GA, et al; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999;94:323–9
   PubMed Web of Science ®Google Scholar
• Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3:145–56
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95–102
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Skouby SO, Heikkinen J, Vaheri R, Mäenpää J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric 2004;7:59–69
   PubMed Web of Science ®Google Scholar
• Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003;188:92–9
   PubMed Web of Science ®Google Scholar
• Simon JA, Symons JP; femhrt Study Investigators. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001;8:321–7
   PubMed Web of Science ®Google Scholar
• Pickar JH, Bottiglioni F, Archer DF. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric 1998;1:130–6
   PubMedGoogle Scholar
• Johnson JV, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause 2002;9: 16–22
   PubMed Web of Science ®Google Scholar
• Stadberg E, Mattsson LA, Uvebrant M. 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23:31–9
   PubMed Web of Science ®Google Scholar
• van de Weijer PH, Barentsen R, de Vries M, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol 1999;93:551–7
   PubMed Web of Science ®Google Scholar
• Hammond CB. Women's concerns with hormone replacement therapy – compliance issues. Fertil Steril 1994;62(6 Suppl 2): 157–60S
   Google Scholar
• Utian WH, Schiff I. North American Menopause Society – Gallup survey on women’s knowledge, information sources and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39–48
   Web of Science ®Google Scholar
• Birkhäuser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–23
   PubMed Web of Science ®Google Scholar
• Board of the International Menopause Society, Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra- low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Archer DF, Rakov V, Lang E; CHOICE Study Investigators. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008;11:63–73
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal Women. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003348.pdf
   Google Scholar
• World Medical Association (WMA). WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General Assembly, Tokyo 2004
   Google Scholar
• ISPE (International Society of Pharmacoepidemiology). Guidelines for Good Pharmacoepidemiology Practices (GPP). Pharmacoepidemiol Drug Saf 2008;17:200–8
   PubMed Web of Science ®Google Scholar
• Eviana® Summary of Product Characteristics. 2011. Available at: http://www.isdin.com/sites/default/files/ftpdf/eviana_eng.pdf
   Google Scholar
• Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50:209–21
   PubMed Web of Science ®Google Scholar